Clinical Trials Logo

Idiopathic Short Stature clinical trials

View clinical trials related to Idiopathic Short Stature.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04020913 Active, not recruiting - Clinical trials for Growth Hormone Deficiency

Skeletal Muscle Effects of GH in Boys

Start date: July 22, 2019
Phase:
Study type: Observational

The purpose of the study is to measure the functional effects of recombinant GH in skeletal muscle, in addition to growth promotion, in short prepubertal boys with either growth hormone deficiency or idiopathic short stature. Patients will be similarly short. The investigators will also compare these values in the short stature cohort to those obtained in testing performed in normally growing age-matched healthy control boys not on GH. The group on GH will be studied before and after 6 and 12 months of GH treatment.

NCT ID: NCT00840944 Active, not recruiting - Clinical trials for Idiopathic Short Stature

A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height

ZomaTrip
Start date: January 2008
Phase: Phase 4
Study type: Interventional

Estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly. Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth hormone for 4 years.